Nordic Issuing

Ongoing case

Invent Medic Sweden AB

Back to all cases

Invent Medic Sweden AB

25 Feb - 18 Mar 2021Exercising of warrants TO 1

Invent Medic develops innovative products with the aim of improving women’s health and quality of life. The company’s products must be safe, effective and easy to use. The finished products in women’s health are sold under the own brand Arcamea. Invent Medical’s first product, Efemia, a CE-marked and patented medical device for stress incontinence (SUI), reduced urine leakage by an average of 77 percent when used in a clinical study. The product is based on the same scientific principle as the TVT method, the main surgical treatment method for SUI.

Read more on the company's website

The offer in summary

Subscription period: 25 February - 18 March 2021

Trading with TO 1: Until 16 March 2021

Subscription price: SEK 6.75

Capital raise (SEK): There are 2,209,590 outstanding warrants of series TO 1. Upon full exercise of all warrants of series TO 1, Invent Medic will receive a maximum of approximately SEK 14.9 million before issue costs.